
FRMSP — Investor Relations & Filings
Formosa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies within the fields of ophthalmology, oncology, and anti-infectives. The company utilizes its proprietary Activus Pure Nano-technology (APNT®) platform to enhance the formulation of poorly soluble drugs, improving bioavailability and efficacy. Its lead product, APP13007, is a clobetasol propionate ophthalmic suspension developed for the treatment of post-operative inflammation and pain following ocular surgery, which has received regulatory approval in the United States. Formosa Pharmaceuticals focuses on the 505(b)(2) regulatory pathway and the development of antibody-drug conjugates (ADCs). The company actively pursues global licensing and co-development partnerships to advance its pipeline of high-value therapeutic assets.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 本公司114年股東常會解除董事(含獨立董事)競業禁止 之限制案 | 2026-05-25 | Chinese | |
| 公告本公司115年股東常會重要決議 | 2026-05-25 | Chinese | |
| 115年第1季海外子公司投資 | 2026-05-12 | Chinese | |
| 115年第1季財務報告書 — 202601_6838_AI1.pdf | 2026-05-12 | Chinese | |
| 115年第1季權益變動表 | 2026-05-11 | Chinese | |
| 115年第1季現金流量表 | 2026-05-11 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47018738 | 本公司114年股東常會解除董事(含獨立董事)競業禁止 之限制案 | 2026-05-25 | Chinese | ||
| 47018732 | 公告本公司115年股東常會重要決議 | 2026-05-25 | Chinese | ||
| 46125730 | 115年第1季海外子公司投資 | 2026-05-12 | Chinese | ||
| 45772860 | 115年第1季財務報告書 — 202601_6838_AI1.pdf | 2026-05-12 | Chinese | ||
| 45746245 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741543 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741357 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45741000 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
| 45751780 | 公告本公司董事會通過115年第一季合併財務報告 | 2026-05-11 | Chinese | ||
| 41265890 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41265882 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 40916642 | 115年4月背書保證與資金貸與 | 2026-05-04 | Chinese | ||
| 40916637 | 115年4月營業收入 | 2026-05-04 | Chinese | ||
| 37237117 | 115年年報及股東會資料 — 2026_6838_20260525F13.pdf | 2026-04-27 | Chinese | ||
| 36052267 | 115年年報及股東會資料 — 2026_6838_20260525FE2.pdf | 2026-04-24 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Sernova Biotherapeutics Inc.
Developing regenerative medicine using the Cell Pouch platf…
|
SVA | CA | Professional, scientific and te… |
|
SHANGHAI INNOSTAR BIO-TECH CO., LTD.
CRO specializing in GLP-compliant preclinical drug safety a…
|
688710 | CN | Professional, scientific and te… |
|
Shanghai Medicilon Inc.
Integrated drug discovery and preclinical services for glob…
|
688202 | CN | Professional, scientific and te… |
|
SHANGHAI MODEL ORGANISMS CENTER, INC.
Develops genetically engineered animal models and provides …
|
688265 | CN | Professional, scientific and te… |
|
SHANGHAI OPM BIOSCIENCES CO., LTD.
Provides cell culture media and CDMO services for biopharma…
|
688293 | CN | Professional, scientific and te… |
|
Shanghai Titan Scientific Co.,Ltd.
Provides scientific research products and integrated labora…
|
688133 | CN | Professional, scientific and te… |
|
Sharp Therapeutics Corp.
Preclinical drug discovery developing small molecule therap…
|
SHRX | CA | Professional, scientific and te… |
|
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
A contract research organization providing comprehensive dr…
|
2395 | JP | Professional, scientific and te… |
|
SHOUYAO HOLDINGS CO.,LTD
Develops small molecule drugs for oncology, metabolic, and …
|
688197 | CN | Professional, scientific and te… |
|
Silence Therapeutics plc
Clinical-stage biotech developing siRNA medicines to silenc…
|
SLN | GB | Professional, scientific and te… |
FRMSP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52643/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52643 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52643 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52643 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52643}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for FRMSP (id: 52643)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.